Qiuhua Deng1, Haihong Yang2, Yongping Lin3, Yuan Qiu2, Xia Gu4, Ping He4, Meiling Zhao2, Hui Wang3, Yunjian Xu3, Yunen Lin4, Juhong Jiang4, Jianxing He2, Jeff X Zhou5. 1. Center for Translational Medicine, The First Affiliated Hospital, Guangzhou Medical University Guangzhou, China. 2. State Key Laboratory of Respiratory Diseases Guangzhou, China ; Cardiothoracic Surgery, The First Affiliated Hospital, Guangzhou Medical University Guangzhou, China. 3. Department of Medical Laboratory, The First Affiliated Hospital, Guangzhou Medical University Guangzhou, China. 4. Department of Pathology, The First Affiliated Hospital, Guangzhou Medical University Guangzhou, China. 5. Ningbo University School of Medicine Ningbo, China.
Abstract
BACKGROUND: Excision repair cross complementation group 1 (ERCC1) is a nucleotide excision repair pathway gene which provides protection against platinum-based chemotherapy-induced DNA damage. METHODS: ERCC1 mRNA expression was quantified by quantitative real-time reverse-transcription PCR in paraffin-embedded non-small cell lung cancer (NSCLC; n = 357), gastric cancer (n = 106), and breast cancer (n = 363) tissues. Survival curves were generated by Kaplan-Meier analysis; Cox proportional multivariate regression analysis was applied. RESULTS: ERCC1 mRNA expression was significantly higher in breast cancer than gastric cancer or NSCLC (both P < 0.0001), but not significantly different in NSCLC and gastric cancer (P = 0.119). In NSCLC, the low ERCC1 group had significantly longer disease free survival (DFS) than the high ERCC1 group (29.1 vs. 21.0 months, P < 0.0001); in the surgery alone and postoperative platinum-containing chemotherapy subgroups, DFS was significantly longer for the low ERCC1 groups than high ERCC1 groups (30.2 vs. 25.1 months, P = 0.018; 27.0 vs. 19.4 months, P < 0.0001, respectively). In gastric cancer patients receiving surgery alone, the low ERCC1 group had significantly longer overall survival than the high ERCC1 group (47.54 vs. 27.47 months, P = 0.018). CONCLUSIONS: High ERCC1 mRNA expression of the NSCLC tumor tissues was associated with poor disease-free survival (DFS), in both the surgery alone and postoperative platinum-containing chemotherapy subgroups. Meanwhile, low ERCC1 mRNA expression had significantly longer overall survival in gastric cancer patients receiving surgery alone. Therefore, ERCC1 expression was a prognostic factor and predictive marker in NSCLC, and gastric cancer after surgery alone, but was not a prognostic factor in breast cancer.
BACKGROUND:Excision repair cross complementation group 1 (ERCC1) is a nucleotide excision repair pathway gene which provides protection against platinum-based chemotherapy-induced DNA damage. METHODS:ERCC1 mRNA expression was quantified by quantitative real-time reverse-transcription PCR in paraffin-embedded non-small cell lung cancer (NSCLC; n = 357), gastric cancer (n = 106), and breast cancer (n = 363) tissues. Survival curves were generated by Kaplan-Meier analysis; Cox proportional multivariate regression analysis was applied. RESULTS:ERCC1 mRNA expression was significantly higher in breast cancer than gastric cancer or NSCLC (both P < 0.0001), but not significantly different in NSCLC and gastric cancer (P = 0.119). In NSCLC, the low ERCC1 group had significantly longer disease free survival (DFS) than the high ERCC1 group (29.1 vs. 21.0 months, P < 0.0001); in the surgery alone and postoperative platinum-containing chemotherapy subgroups, DFS was significantly longer for the low ERCC1 groups than high ERCC1 groups (30.2 vs. 25.1 months, P = 0.018; 27.0 vs. 19.4 months, P < 0.0001, respectively). In gastric cancerpatients receiving surgery alone, the low ERCC1 group had significantly longer overall survival than the high ERCC1 group (47.54 vs. 27.47 months, P = 0.018). CONCLUSIONS: High ERCC1 mRNA expression of the NSCLC tumor tissues was associated with poor disease-free survival (DFS), in both the surgery alone and postoperative platinum-containing chemotherapy subgroups. Meanwhile, low ERCC1 mRNA expression had significantly longer overall survival in gastric cancerpatients receiving surgery alone. Therefore, ERCC1 expression was a prognostic factor and predictive marker in NSCLC, and gastric cancer after surgery alone, but was not a prognostic factor in breast cancer.
Authors: Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria Journal: N Engl J Med Date: 2006-09-07 Impact factor: 91.245
Authors: Joachim Pfannschmidt; Thomas Muley; Heinrich Bülzebruck; Hans Hoffmann; Hendrik Dienemann Journal: Lung Cancer Date: 2006-11-22 Impact factor: 5.705
Authors: Edmund S Kassis; Ara A Vaporciyan; Stephen G Swisher; Arlene M Correa; B Nebiyou Bekele; Jeremy J Erasmus; Wayne L Hofstetter; Ritsuko Komaki; Reza J Mehran; Cesar A Moran; Katherine M Pisters; David C Rice; Garrett L Walsh; Jack A Roth Journal: J Thorac Cardiovasc Surg Date: 2009-05-28 Impact factor: 5.209
Authors: J Matsubara; T Nishina; Y Yamada; T Moriwaki; T Shimoda; T Kajiwara; T E Nakajima; K Kato; T Hamaguchi; Y Shimada; Y Okayama; T Oka; K Shirao Journal: Br J Cancer Date: 2008-01-29 Impact factor: 7.640
Authors: A Marcell Szász; András Lánczky; Ádám Nagy; Susann Förster; Kim Hark; Jeffrey E Green; Alex Boussioutas; Rita Busuttil; András Szabó; Balázs Győrffy Journal: Oncotarget Date: 2016-08-02